Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

297.32 -2.47 (-0.82%)
Streaming Delayed Price Updated: 10:56 AM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
 
Via Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
The news also benefits Biogen's partner Eisai and rival Eli Lilly. 
Via Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Biogen Unusual Options Activity For May 26
 
Via Benzinga
Analyst Ratings for Biogen
 
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today
 
Via Benzinga
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak. 
Via The Motley Fool
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
(BIIB) - Analyzing Biogen's Short Interest
 
Via Benzinga
P/E Ratio Insights for Biogen
 
Via Benzinga
Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8
Looking for longs on the way up into wave (3), as long as every downside pullback is a three wave move. 
Via Talk Markets
Biogen Unusual Options Activity
 
Via Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
An analyst says Lilly's donanemab could become a blockbuster in its second year on the market. 
Via Investor's Business Daily
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
There's no rule that says a market must have only one winner. 
Via The Motley Fool
3 Reasons to Buy Biogen Stock (and 1 to Sell)
The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi. 
Via The Motley Fool
Here’s What Eli Lilly’s Latest Clinical Win Means For Investors
The biotech's prospects continue to get brighter. 
Via The Motley Fool
Why Eli Lilly Stock Is Bolting Higher Today
Lilly's Alzheimer's disease candidate might be a best-in-class option for patients. 
Via The Motley Fool
Biogen Unusual Options Activity For May 03
 
Via Benzinga
Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors. 
Via The Motley Fool
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
 
Via Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of  
Via Benzinga
Another Sucess In Alzheimer’s Disease
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments? 
Via Talk Markets
Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises
Eli Lilly is focusing on proteins associated with Alzheimer's disease. 
Via Investor's Business Daily
Microsoft, Snap And 2 Other Stocks Insiders Are Selling
The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.